Application of Radelumin(PSMA-1007) combined with MRS(Magnetic resonance spectroscopy) in assessment of benign and malignant prostate cancer.

Chih-Yi Wu1, Yu-Ming Fan2,3(co-first author), Chun-Hou Liao3,4, Ya-Ting Huang1,5, Ya-Yao Huang1,6, Jia-Hsin Fang2

1Primo Biotechnology Co., Ltd
2Department of Nuclear Medicine of Cardinal Tien Hospital
3School of Medicine, College of Medicine, Fu Jen Catholic University
4Department of Urology of Cardinal Tien Hospital
5Department of Medical Education and Research, Camillian Saint Mary’s Hospital
6Institute of Medical Device and Imaging, National Taiwan University College of Medicine

This study poster was presented at the 2024 Annual Meeting of the Taiwan Urological Association(TUA).

F-18 PSMA-1007 (PSMA-1007) is a PET tracer widely used for the detection of metastatic castration-resistant prostate cancer (mCRPC) and suspected biochemical recurrent prostate cancer (BCRPCa) and is known for its exceptional specificity and superior sensitivity.

Magnetic resonance spectroscopy (MRS) allows in-depth observation of specific biochemical substances in prostate cancer, but has not gained acceptance due to technical and equipment limitations.

However, previous experience with chemical substances such as choline in combination with chemical shift imaging (CSI) and T1 mapping to eliminate scar interference has shown promising results. Given the excellent specificity and sensitivity of PSMA-1007, there is potential to develop a more convenient and painless diagnostic tool for prostate cancer in the future.